Top Markets
Coin of the day
Liminal BioSciences Inc. Liminal BioSciences Inc.

Liminal BioSciences Inc.

LMNL
Peringkat dalam Saham #38952
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm,... Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
Harga Saham
$8.50
Terakhir disinkronkan: 2023-09-26
Kapitalisasi Pasar
$719.10K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan Liminal BioSciences Inc. (LMNL)

Kategori

Rasio P/B untuk Liminal BioSciences Inc. (LMNL)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Liminal BioSciences Inc., rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk Liminal BioSciences Inc. dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE